Q-omics provides the consensus-scored RPL36AP26 profile across patient tissues and cancer cell-line models. RPL36AP26 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, RPL36AP26 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, RPL36AP26 RNA expression shows 11,403 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, COAD, and THYM as cancer lineages where RPL36AP26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL36AP26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL36AP26 survival associations across molecular data types. RPL36AP26 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL36AP26 RNA expression–survival associations across cancer types. High RPL36AP26 expression shows unfavorable associations in KIRP, UCEC and ACC, but favorable associations in CESC, LUSC and SKCM. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for RPL36AP26 RNA expression.
This table summarizes RPL36AP26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL36AP26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL36AP26 shows higher tumor expression in COAD, KIRC, LIHC, LUAD, KIRP and READ. The COAD box plot shows higher RPL36AP26 RNA expression in tumor versus normal tissue (log2 FC = +0.693, t-test p < 0.001).
This table shows molecular features associated with RPL36AP26 in patient tissues and cancer cell lines. In patient samples, RPL36AP26 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
